Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety of topically applied SP-303 gel and to compare the efficacy of SP-303 gel in combination with acyclovir, relative to acyclovir alone, for the treatment of recurrent Herpes Simplex Virus (HSV) 1 and 2 infections, affecting the genital, perianal and neighboring areas, in patients with AIDS.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shaman Pharmaceuticals
• Treatments: Acyclovir

Criteria

Inclusion Criteria

Patients must have:

• AIDS, according to the CDC criteria.

• Documented recurrent (at least 1 prior episode) perineal (genital, perianal and neighboring areas) mucocutaneous herpes simplex virus (HSV) types 1 or 2 infection in the active phase.

• Duration of current episode of recurrent HSV lesions of 3 days or less.

• Ability to read and write, must be intellectually competent, and able to understand the purposes and risks of the study.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

• Active internal anal or rectal herpes.

• Inability to comply with protocol.

• Impaired renal function.

Patients with the following prior conditions are excluded:

• Prior episode of recurrent genital herpes infection with documented clinical failure of acyclovir as a treatment regimen.

• Uncompensated hepatic, cardiac, or renal failure within 1 month of the study.

• History of hypersensitivity to acyclovir.

• Previous enrollment in this study.

1. Treatment with another medication (topical, oral, or intravenous) with known anti-HSV activity within the past 5 days.

• Systemic immunomodulatory therapy within 30 days prior to study.

• Previous treatment with SP-303.

Required:

Unchanged antiretroviral therapy for the 2 weeks prior to study.